OGN and Myocardial fibrosis: Silencing of osteoglycin has been suggested to exert inhibitory effects on myocardial fibrosis and EMT in a mouse model of myocarditis via downregulating levels of TGF-β1, FSP-1, α-SMA and upregulating levels of E-cadherin [20].